Barclays
FTH

Barclays’s Faeth Therapeutics FTH Stock Holding History

Barclays’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$310K Buy
+12,412
New +$287K ﹤0.01% 3478
2025
Q2 		– Sell
-128
Closed -$1.01K – 5520
2025
Q1 		$1.01K Buy
+128
New +$1.22K ﹤0.01% 5049
2022
Q3 		– Sell
-10
Closed – – 5110
2022
Q2 		$0 Sell
10
-160
-94% -$6K ﹤0.01% 5236
2022
Q1 		$8K Buy
+170
New +$13.5K ﹤0.01% 4639

Other funds holding FTH

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

Barclays's FTH Position: Q2 2026 in Review

Barclays opened a new position in Faeth Therapeutics (FTH) in Q2 2026: 12,412 shares worth $310K. The stake represents ﹤0.01% of the portfolio and ranks #3478 among its holdings. This is a return to the name: Barclays previously reported a position in FTH as recently as Q1 2025.

Barclays first reported a position in FTH in Q1 2022 and has held it in 4 quarters since. 45 funds tracked by Wall St. Rank hold FTH as of Q2 2026.

  • Barclays held 12,412 shares of Faeth Therapeutics worth $310K as of Q2 2026.
  • Faeth Therapeutics was a new Barclays position in Q2 2026.
  • Faeth Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3478 holding.
  • Barclays first reported a position in Faeth Therapeutics in Q1 2022 and has held it in 4 quarters since.
  • 45 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.